Research programme: respiratory virus therapeutics - Ansun Biopharma

Drug Profile

Research programme: respiratory virus therapeutics - Ansun Biopharma

Alternative Names: ANSX EV68; ANSX MP10; ANSX RV14; AXSXS68; Inviridin; NEX-PIN; NEX-VAC; Viracidin

Latest Information Update: 06 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NexBio
  • Developer Ansun Biopharma
  • Class Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Enterovirus infections; Metapneumovirus infections; Respiratory syncytial virus infections
  • Discontinued Influenza virus infections

Most Recent Events

  • 30 Jul 2016 Discontinued - Preclinical for Influenza virus infections in USA (unspecified route)
  • 30 Jul 2016 Preclinical trials in Respiratory syncytial virus infections in USA (unspecified route)
  • 27 Jul 2015 Preclinical development is ongoing for metapneumovirus infections and enterovirus infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top